Kusumi, Eiji
Murayama, Anju http://orcid.org/0000-0002-4279-4748
Kamamoto, Sae
Kawashima, Moe http://orcid.org/0000-0002-9857-1236
Yoshida, Makoto
Saito, Hiroaki
Sawano, Toyoaki
Yamashita, Erika
Tanimoto, Tetsuya
Ozaki, Akihiko
Article History
Received: 7 January 2022
Revised: 22 March 2022
Accepted: 23 March 2022
First Online: 7 April 2022
Competing interests
: For the financial competing interests, EK received personal fees from Otsuka Pharmaceutical Co., Ltd outside the scope of the submitted work. HS received personal fees from Taiho Pharmaceutical Co. Ltd outside the scope of the submitted work. AO and TT received personal fees from Medical Network Systems outside the scope of the submitted work. TT also received personal fees from Bionics Co. Ltd, outside the scope of the submitted work. Regarding non-financial competing interests among the study authors, all are engaged in ongoing research examining financial and non-financial competing interests among healthcare professionals and pharmaceutical companies in Japan. Individually, AM, SK, HS, TS, TT, and AO have contributed to several published studies assessing competing interests and quality of evidence among clinical practice guideline authors in Japan and the United States. Among their previous articles, the authors have self-cited several articles in this study to gain deeper insights and explain the context of financial competing interests among healthcare professionals in Japan. EK was a hematology specialist board-certified by the Japanese Society of Hematology. The other authors have no example competing interests to disclose.